Clinical Trial Update: Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design [Phase 3]

View source ↗

Summary

Phase 3 randomized withdrawal trial assessing esreboxetine for fibromyalgia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• esreboxetine (esreboxetine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Fibromyalgia | Phase 3 | Status: RECRUITING